期刊文献+

血清肺癌标志物阳性表达率与肺癌分型及同侧纵隔淋巴结转移关系的分析研究 被引量:2

下载PDF
导出
摘要 目的:探讨肺癌患者不同血清学肺癌标志物阳性表达率与肺癌病理分型及有无同侧纵隔淋巴结转移之间的关系。方法:对112例肺癌患者术前进行放免法测定血清细胞角质片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、促肾上腺皮质激素(ACTH)样物的浓度,施行肺癌根治术,术后病理切片诊断病理分型及有无同侧纵隔淋巴结转移,统计分析术前肺癌患者不同血清学肺癌标志物阳性表达率之间的差异与肺癌病理分型及有无同侧纵隔淋巴结转移的关系。结果:CYFRA21-1在非小细胞肺癌(NSCLC)组中阳性率高于小细胞肺癌(SCLC)组(P<0.01),在NSCLC组中病理学证明有同侧纵隔淋巴结转移(P-N2)比病理学未证明有同侧纵隔淋巴结转移(P-N0-1)的CYFRA21-1阳性表达率高(P<0.05);NSE在SCLC组中阳性率高于NSCLC(P<0.01),在SCLC组中P-N2比P-N0-1的NSE阳性表达率高(P<0.05);ACTH样物的阳性表达率在NSCLC和SCLC及P-N2和P-N0-1之间差异无显著性(P>0.05)。结论:CYFRA21-1阳性表达多提示病理分型为NSCLS,易发生同侧纵隔淋巴结转移,若同时NSE亦为阳性表达,则可进一步确定同侧纵隔淋巴结转移的存在;NSE阳性表达多提示病理分型为SCLC,更易发生同侧纵隔淋巴结转移;ACTH样物的阳性表达对肺癌的病理分型及有无同侧纵隔淋巴结转移无预测意义。
出处 《实用医学杂志》 CAS 2005年第12期1272-1274,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献6

  • 1Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: devita VT, Helman, s, Rosenberg SA, eds. cancer principles and practice of oncology. Philadelphia: Lippincott, 1993:673-758.
  • 2王洲,马传栋,殷洪年,张军.肺癌纵隔淋巴结转移的临床预测[J].中国肺癌杂志,2001,4(2):105-108. 被引量:14
  • 3杜同信,王自正,田韧.肺癌患者NSE、CYFRA21-1、CEA RIA水平变化的分析研究[J].标记免疫分析与临床,2000,7(2):104-105. 被引量:8
  • 4Ebert W, Muley T, Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?Anticancer Res, 1996, 16(4B): 2161 - 2168.
  • 5Plebani M, Basso D, Navaglia F, et al. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer, 1995, 72(1 ): 170 - 173.
  • 6Sundaresan V, Reeve JG, Stenning S, et al. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer, 1991, 64(2): 333 - 338.

二级参考文献13

  • 1BodyJJ,SculierJP,RaymakersNetal.Evaluationofsquamouscellcarcinomaantigenasanewmarkerforlungcancer.Cancer,1990;65:1552~1556
  • 2StieberP,HasholznerU,BodenmullerHetal.CYFRA21-1anewmarkerinlungcancer.Cancer,1993;72:707~713
  • 3BroersJLV,RotMK,OostendorpTetal.Immunocytochemicaldetectionofhumanlungcancerheterogeneityusingantibodiestoepithelial,neuronal,andneuroendocrineantigens.CancerRes,1987;47:3225~3234
  • 4Suzuki K,Nagai K,Yoshida J,et al.Clinical predictors of N2 disease in the setting of anegative computed tomographic scan in patients with lung cancer[].Journal of Thoracic and Cardiovascular Surgery.1999
  • 5Naruke T,Suematu K,Ishikawa S.Lymph node mapping and curability at various levels of metastasis in resected lung cancer[].Journal of Thoracic and Cardiovascular Surgery.1978
  • 6Graham ANJ,Chan KJM,Pastorino U,et al.Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer[].Journal of Thoracic and Cardiovascular Surgery.1999
  • 7Daly BDT,Mueller JD,Faling LJ,et al.N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest[].Journal of Thoracic and Cardiovascular Surgery.1993
  • 8The World Health Organization: Histological Typing of Lung Cancer. American Journal of Clinical Pathology . 1982
  • 9Lewis JW Jr,Pearlberg JL,Beute GH,et al.Can computed tomography of chest stage lung cancer? -yes and no[].The Annals of Thoracic Surgery.1990
  • 10Mounatain CF.Revision in the international system for staging lung cancer[].Chest.1997

共引文献20

同被引文献16

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部